恒瑞医药(600276.SH)：富马酸泰吉利定注射液获得药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for the clinical trial of Fumaric Acid Targinine Injection, marking a significant step in the development of innovative pain relief medications in China [1] Group 1: Company Developments - The company will soon initiate clinical trials for Fumaric Acid Targinine Injection, which is a μ-opioid receptor (MOR) biased small molecule agonist [1] - This product is set to be approved for market launch in China in January 2024, representing the first domestically developed Class 1 opioid analgesic innovation [1]